Abstract: Objective To investigate the effects of ceftazidime combined amikacin on serum levels of hs-CRP,PCT,IL-6 and prognosis of patients with leukemia after leukemia chemotherapy. Methods Sixty-two patients with leukemia after leukemia chemotherapy in Ningbo Yinzhou people's hospital from March,2013 to April,2015 were selected and randomly divided into two groups.The control group was given ceftazidime,and research group was given amikacin combined ceftazidime.Both groups were treated for 1 week.The clinical efficacy,serum hs-CRP,IL-6 and PCT levels,adverse reactions incidence,survival rate after 12 months of two groups were compared. Results The effective rate of research group was 83.87%(26/31),which was significantly higher than that of control group[61.29%(19/31)],P<0.05.After treatment,the serum hs-CRP,IL-6 and PCT levels of two groups were significantly reduced(P<0.05),and serum hs-CRP,IL-6 and PCT levels of research group were significantly lower than control group(P<0.05).The adverse reaction incidence of research group was 12.90%(4/31),and adverse reaction incidence of control group was 9.67%(3/31),there was no significant difference between two groups.The survival rate of research group was 87.10%(27/31),which was significantly higher than that of control group 64.52%(20/31),P<0.05. Conclusion Amikacin combined ceftazidime could effectively reduce serum hs-CRP,PCT and IL-6 levels of patients with leukemia after leukemia chemotherapy,enhance the therapeutic effect and survival rate,improve the prognosis.